Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high255.00 01/12/16
52 week low78.75 04/01/16
52 week change 30.00 (21.82%)
4 week volume162,389 08/11/16

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
28/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
15/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

US Distribution Agreement: Cholesterol Self-test

RNS Number: 6905Q Akers Biosciences, Inc. 01 December 2016 1 December 2016 This announcement contains inside information Akers Biosciences, Inc. US Distribution Agreement for Rapid Cholesterol Self-test Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has signed a ...

Akers Bio completes BreathScan DKA trial

Akers Biosciences has completed a clinical trial for BreathScan DKA, the first single-use, non-invasive breath test to rapidly...

Clinical Trial for BreathScan DKA Completed

RNS Number: 2656Q Akers Biosciences, Inc. 28 November 2016 28 November 2016 This announcement contains inside information Akers Biosciences, Inc. Clinical Trial for Diabetic Ketoacidosis Breath Test Completed Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio " or the "Company"), a developer of rapid health information technologies, has...

Notice of AGM

RNS Number: 0360P Akers Biosciences, Inc. 14 November 2016 Akers Biosciences, Inc. Notice of Annual General Meeting Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that a notice convening an Annual General Meeting ("AGM") of the Company will be ava...

Akers Bio revenues up 262%

Akers Biosciences reports total revenue of $613,198 for the third quarter - up 262% and all from product sales. Sales of its fl...

Akers Bio revenues up 262%

3rd Quarter Results

RNS Number: 0297P Akers Biosciences, Inc. 14 November 2016 Embargoed: 0700hrs 14 November 2016 This announcement contains inside information Akers Biosciences, Inc. Financial Results for the Third Quarter Ended September 30, 2016 Sales of Flagship Rapid HIT Test +341% over Q3 2015 - Total Revenue +262% Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: A...

Akers Bio schedules Q3 results

Akers Biosciences, a developer of rapid health information technologies, will publish its third quarter results for the three m...

Equity Research (AKR)

Akers Biosciences Inc.
18/08/2016
Physiomics* (PYC.L) 0.04p £1.22m The computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials...
Akers Biosciences Inc.
11/08/2016
ValiRx (Val.L) 39p £4.37m The life science company, which focuses on clinical stage cancer therapeutic development has received regulatory approval for its VAL401 Phase IIB Clinical Trial in Georgia...

Latest discussion posts More

  • Exciting RNS just out

    Worth noting in particular that First Check are a subsidiary of the mighty Alere ...
    1-Dec-2016
    gretel
  • New interview with CEO

    Gormally comes across extremely well. Certainly lots to look forward to. And more optimism about the $2m Chinese sale coming through this quarter, which will be great news ...
    16-Nov-2016
    gretel
  • Q3 conference call transcript

    AKR definitively say that Q4 "is expected to be profitable", and that the rest of the $2.5m Chinese order will be received this quarter. So these things had better happen. I ...
    15-Nov-2016
    gretel

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..
LLOYDS GRP.26%
ID:ISIN:GB00B142G99420%
BP16%
NATIONAL GRID16%
ORMONDE MINING13%

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR